Penn Medicine The Intersection of Hypertension, Diabetes, and Lipids Everything You Need to Know in Preventive Cardiology in 2021

Friday, October 1, 2021, 7:45 AM – 2:00 PM EST, Live, Virtual, Philadelphia, PA

 Cardiovascular disease is the leading cause of death in the United States. Hypertension and diabetes are among the foremost risk factors for the development of cardiovascular diseases, including stroke, peripheral artery disease, and heart attack. Several advances have been made in recent years to improve our ability to prevent the development and progression of cardiovascular disease. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease.

The focus of the program will be on the use of SGLT 2 Inhibitors and GLP-1 agonists to reduce the risk of cardiovascular disease and progression of kidney disease, monitoring and management of hypertension in special patient populations, and common lipid issues in patient care.

1. Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations
2. Identify appropriate blood pressure goals and management in several special patient populations
3. Describe the controversies regarding the appropriate screening, confirmatory testing, and management of patients at risk for primary aldosteronism
4. Achieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia
5. Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention